SAPPHIRE Study - A Phase II Randomized Study Comparing the Efficacy and Safety of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in the Patients With Chemotherapy-naive Unresectable Advanced Recurrent Colorectal Carcinoma of KRAS Wild-type After 6 Cycles of Combination Therapy With mFOLFOX6 +

Trial Profile

SAPPHIRE Study - A Phase II Randomized Study Comparing the Efficacy and Safety of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in the Patients With Chemotherapy-naive Unresectable Advanced Recurrent Colorectal Carcinoma of KRAS Wild-type After 6 Cycles of Combination Therapy With mFOLFOX6 +

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Levofolinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms SAPPHIRE
  • Sponsors Takeda
  • Most Recent Events

    • 08 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 10 Apr 2017 Planned number of patients changed from 100 to 164.
    • 07 Apr 2017 Planned End Date changed from 1 Sep 2017 to 31 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top